tradingkey.logo

Aldeyra Therapeutics Receives Fast Track Designation For Adx‑2191 For The Treatment Of Retinitis Pigmentosa

ReutersAug 19, 2025 11:39 AM

- Aldeyra Therapeutics Inc ALDX.O:

  • ALDEYRA THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FOR ADX‑2191 FOR THE TREATMENT OF RETINITIS PIGMENTOSA

  • ALDEYRA THERAPEUTICS INC - PHASE 2/3 TRIAL OF ADX-2191 EXPECTED TO START IN 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI